Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
Kazia Therapeutics Limited
Institut Bergonié
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
Labcorp Corporation of America Holdings, Inc
Cedars-Sinai Medical Center
Sarcoma Oncology Research Center, LLC
Ann & Robert H Lurie Children's Hospital of Chicago
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
Stanford University
Taproot Health
National Cancer Institute (NCI)
University Hospital, Antwerp
Leiden University Medical Center
Emory University
Xencor, Inc.
Gene Surgery LLC
Cedars-Sinai Medical Center
TransThera Sciences (Nanjing), Inc.
Albert Einstein College of Medicine
Masonic Cancer Center, University of Minnesota
Corvus Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, LLC
Prelude Therapeutics
M.D. Anderson Cancer Center
Sumitomo Pharma America, Inc.
Children's Oncology Group
Emory University
Tempest Therapeutics
Eastern Cooperative Oncology Group
Children's National Research Institute
Florida International University
Quadriga Biosciences, Inc.
Ludwig Institute for Cancer Research
Scripps Health
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
Roswell Park Cancer Institute
Pfizer
University of South Florida
Case Comprehensive Cancer Center
Celgene
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins